Prospective Grant of Exclusive License: Long-Acting Testosterone Androgenic Compounds and Pharmaceutical Compositions Thereof

Riepilogo

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in: U.S. Patent 4,948,790, issued August 14, 1990 entitled, ``Long-Acting Androgenic Compounds, and Pharmaceutical Compositions Thereof'' to N.V. Organon, having a place of business in The Netherlands. The United States of America is an assignee of the patent rights in this invention.